SS-31 (Elamipretide) — Peptide Intelligence Monograph

Short description

The Evidence Behind the Hype.

A physician-reviewed, evidence-based examination of SS-31 (elamipretide) from the Founder’s Institute of Medicine & Education.

This digital monograph separates findings from human clinical studies from mechanistic and preclinical research, emerging therapeutic hypotheses, and claims that remain unproven.

Full product description

SS-31 has attracted attention as a mitochondria-targeting peptide. But what does the evidence actually show?

SS-31, also known as elamipretide, is a mitochondria-targeting peptide studied for its interactions with the inner mitochondrial membrane and cardiolipin, with potential downstream effects on mitochondrial structure, energetics, and cellular function.

Its biological rationale is compelling—but mechanistic plausibility is not the same as demonstrated clinical benefit.

The SS-31 (Elamipretide) Peptide Intelligence Monograph examines the evidence systematically, distinguishing laboratory findings and biological mechanisms from observations in human studies and conclusions that can actually be supported clinically.

Inside the monograph:

• SS-31 structure, pharmacology, and mitochondrial targeting
• Cardiolipin and inner mitochondrial membrane biology
• Proposed effects on mitochondrial energetics and oxidative stress
• Preclinical evidence across organ systems
• Human clinical-trial evidence
• Investigational disease-specific applications
• Safety and tolerability findings
• Regulatory and investigational status
• Limitations, uncertainties, and important evidence gaps
• Claim-by-claim FIPES evidence grading
• What we know, what we do not know, and what research is still needed

Physician reviewed. Evidence graded. No protocols. No dosing instructions. No promotional claims.

This publication is intended for education and scientific evidence review. It is not medical advice and does not recommend or instruct the use of SS-31 (elamipretide).